



Substitute for form 1449B-PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	08/573,569
Filing Date	12/14/1995
First Named Inventor	Hunein F. Maassab
Art Unit	1648
Examiner Name	Parkin, Jeffrey
Attorney Docket Number	UM 2002.01

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published
J	1	ALEXANDROVA, G. I., et al., "Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates" (1990) <i>Vaccine</i> 8:61-64
	2	BELSHE, R.B., et al. "Immunization of Infants and Young Children with Live Attenuated Trivalent Cold-Recombinant Influenza A H1N1, and B Vaccine" (1992) <i>J. Infectious Diseases</i> 165:727-732
	3	CLAVO, A.C., et al., "A persistent infection in MDCK cells by an influenza type B virus" (1993) <i>Virus Research</i> 29: 21-31
	4	CLEMENTS, M. L., et al., "Evaluation of Bovine, Cold-Adapted Human, and Wild-Type Human Parainfluenza Type 3 Viruses in Adult Volunteers and in Chimpanzees" (1991) <i>J. of Clinical Microbiology</i> 29:1175-1182
	5	CLEMENTS, M. L., et al., "Evaluation of the Infectivity, Immunogenicity, and Efficacy of Live Cold-Adapted Influenza B/Ann Arbor/1/86 Reassortant Virus Vaccine in Adult Volunteers" (1990) <i>J. of Infectious Diseases</i> 161:869-877
	6	EDWARDS, K.M., et al., "Safety and Immunogenicity of Live Attenuated Cold-Adapted Influenza B/Ann Arbor/1/86 Reassortant Virus Vaccine in Infants and Children" (1991) <i>J. of Infectious Diseases</i> 163:740-745
	7	GORSE, G.J., et al., "Superiority of Live Attenuated compared with Inactivated Influenza A Virus Vaccines in Older, Chronically Ill Adults" (1991) <i>Chest</i> 100:977-984
	8	KARRON, R.A., et al., "A Live Attenuated Bovine Parainfluenza Virus Type 3 Vaccine Is Safe, Infectious, Immunogenic, and Phenotypically Stable in Infants and Children" (1995) <i>J. of Infectious Diseases</i> 171:1107-1114
	9	MAASSAB, H.F., et al., "Cold-Adapted Influenza Viruses for Use as Live Vaccines for Man" (1990) <i>Viral Vaccines</i> 203-242
	10	MAJDE, J.A., et al., "Detection of toxic viral-associated double-stranded RNA (dsRNA) in influenza-infected lung" (1991) <i>Microbial Pathogenesis</i> 10:105-115
	11	Sequential Analysis of the V3 Loop in HIV-1 From A Pediatric Population
	12	MASSEY J., et al., Abstract from General Mtg. "Genetic Variability in the HIV-1 Principle Neutralizing Domain from North American and African Isolates" (1993)
	13	POWERS, D.C., et al., "In Elderly Persons Live Attenuated Influenza A Virus Vaccines So Not Offer an Advantage over Inactivated Virus Vaccine in Inducing Serum or Secretory Antibodies of Local Immunologic Memory" (1991) <i>J. of Clinical Microbiology</i> 29:498-505
	14	RISER, B.L., et al., "Differential Interaction of virulent and Attenuated Influenza Virus Strains with Ferret Alveolar Macrophages: Possible Role in Pathogenicity" (1990) <i>J. of Infectious Diseases</i> 161:699-705
	15	SHAW, M.W., et al., "New Aspects of Influenza Viruses" (1992) <i>J. of Clinical Microbiology</i> 5:74-92
	16	SNYDER, M.H., et al., "A 36 nucleotide deletion mutation in the coding region of the NS1 gene of an influenza A virus RNA segment 8 specifies a temperature-dependent host range phenotype" (1990) <i>Virus Research</i> 15:69-84
	17	SNYDER, M.H., et al., "Attenuation and Phenotypic Stability of Influenza B/Texas/1/84 Cold-Adapted Reassortant Virus: Studies in Hamsters and Chimpanzees" (1989) <i>J. of Infectious Diseases</i> 4:604-610
	18	Steinhoff et al. (1992) "Cold-Adapted Live Attenuated Influenza Virus Vaccine is Safe and Immunogenic in 2-5 Month Old Infants" Research Paper, Mtg of Am. Ped. Society, Ped. Res. 31(2) 179A
	19	TREANOR, J.J., et al., "Protective Efficacy of Combined Live Intranasal and Inactivated Influenza A Virus Vaccines in the Elderly" (1992) <i>Annals of Internal Medicine</i> 117:625-633
	20	TREANOR, J.J., et al., "Evaluation of Live Attenuated Cold-Adapted Influenza B/Yamagata/16/88 Reassortant Virus Vaccine in Healthy Adults" (1993) <i>J. of Infectious Diseases</i> 168:455-459
	21	VAN WYKE, K.L., et al., "Antibody Responses of Humans and Nonhuman Primates to Individual Antigenic Sites of the Hemagglutinin-Neuraminidase and Fusion Glycoproteins after Primary Infection or Reinfection with Parainfluenza Type 3 Virus" (1990) <i>J. of Virology</i> 64:3833-3843
	22	VAN WYKE, K.L., et al., "Attenuation of Bovine Parainfluenza Virus Type 3 in Nonhuman Primates and Its Ability to Confer Immunity to Human Parainfluenza Virus Type 3 Challenge" (1988) <i>J. of Infectious Diseases</i> 157:655-662



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	08/573,569
Filing Date	12/14/1995
First Named Inventor	Hunein F. Maassab
Art Unit	1648
Examiner Name	Parkin, Jeffrey
Attorney Docket Number	UM 2002.01

23	DOWLING-WHITAKER, P., et al., "The Genes Associated with Trans-dominance of the Influenza A Cold-Adapted Live Virus Vaccine" (1901) <i>Virology</i> 180:81-87
24	DOWLING-WHITAKER, P., et al., "Dominant-Negative Mutants as Antiviral Agents: Simultaneous Infection with the Cold-Adapted Live-Virus Vaccine for Influenza A Protects Ferrets from Disease Produced by Wild-Type Influenza A" (1991) <i>J. of Infectious Diseases</i> 164:1200-1202
25	YAMANE N., et al., "(1992) Conf. Paper 32nd Interscience Conf. on Micro 32(0) Oct. 11 to Oct. 14, (1992), "Five-Season Evaluation of Cold Adapted Line Influenza Vaccines Among Japanese Volunteers Against Natural Epidemics"
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	

Examiner's Signature	Date Considered 04/11/07
----------------------	--------------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.